These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 25248112)
1. BRCA1/2 mutation status is an independent factor of improved survival for advanced (stage III-IV) ovarian cancer. Rudaitis V; Zvirblis T; Kanopiene D; Janulynaite D; Griskevicius L; Janavicius R Int J Gynecol Cancer; 2014 Oct; 24(8):1395-400. PubMed ID: 25248112 [TBL] [Abstract][Full Text] [Related]
2. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760 [TBL] [Abstract][Full Text] [Related]
3. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer. Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS J Ovarian Res; 2019 May; 12(1):40. PubMed ID: 31064392 [TBL] [Abstract][Full Text] [Related]
4. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery. Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109 [TBL] [Abstract][Full Text] [Related]
5. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. Yang D; Khan S; Sun Y; Hess K; Shmulevich I; Sood AK; Zhang W JAMA; 2011 Oct; 306(14):1557-65. PubMed ID: 21990299 [TBL] [Abstract][Full Text] [Related]
6. Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer. Bookman MA; Tyczynski JE; Espirito JL; Wilson TW; Fernandes AW Gynecol Oncol; 2017 Jul; 146(1):58-63. PubMed ID: 28454659 [TBL] [Abstract][Full Text] [Related]
7. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer]. Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524 [TBL] [Abstract][Full Text] [Related]
8. BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study. Harter P; Johnson T; Berton-Rigaud D; Park SY; Friedlander M; Del Campo JM; Shimada M; Forget F; Mirza MR; Colombo N; Zamagni C; Chan JK; Imhof M; Herzog TJ; O'Donnell D; Heitz F; King K; Stinnett S; Barrett C; Jobanputra M; Xu CF; du Bois A Gynecol Oncol; 2016 Mar; 140(3):443-9. PubMed ID: 26740259 [TBL] [Abstract][Full Text] [Related]
9. Centralisation of epithelial ovarian cancer surgery: results on survival from a peripheral teaching hospital. van Vliet MM; Schreuder HW; Pasker-de Jong PC; Duk MJ Eur J Obstet Gynecol Reprod Biol; 2015 Sep; 192():72-8. PubMed ID: 26177496 [TBL] [Abstract][Full Text] [Related]
10. Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage Müllerian cancer. Mahdi H; Gockley A; Esselen K; Marquard J; Nutter B; Yang B; Hinchcliff E; Horowitz N; Rose PG Gynecol Oncol; 2015 Dec; 139(3):407-12. PubMed ID: 26210778 [TBL] [Abstract][Full Text] [Related]
11. Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review. García-Sáenz JA; Custodio A; Casado A; Vidart JA; Coronado PJ; Martín M; López-Tarruella S; Puente J; Fernández C; Díaz-Rubio E Clin Transl Oncol; 2011 Feb; 13(2):121-32. PubMed ID: 21324801 [TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer. Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454 [TBL] [Abstract][Full Text] [Related]
13. Comparison of Clinical Outcomes of Eoh KJ; Park HS; Park JS; Lee ST; Han J; Lee JY; Kim SW; Kim S; Kim YT; Nam EJ Cancer Res Treat; 2017 Apr; 49(2):408-415. PubMed ID: 27488874 [TBL] [Abstract][Full Text] [Related]
14. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Zhang J; Liu N; Zhang A; Bao X J Obstet Gynaecol Res; 2018 Sep; 44(9):1808-1816. PubMed ID: 30019801 [TBL] [Abstract][Full Text] [Related]
15. TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer. Zhang GN; Liu H; Huang JM; Wang L; Zhao JS; Li C; Mi K; Zhu Y; Cheng J; Zha X Gynecol Oncol; 2014 Mar; 132(3):752-7. PubMed ID: 24463159 [TBL] [Abstract][Full Text] [Related]
16. Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status. Kotsopoulos J; Rosen B; Fan I; Moody J; McLaughlin JR; Risch H; May T; Sun P; Narod SA Gynecol Oncol; 2016 Jan; 140(1):42-7. PubMed ID: 26556769 [TBL] [Abstract][Full Text] [Related]
17. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer. Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815 [TBL] [Abstract][Full Text] [Related]
18. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. Alsop K; Fereday S; Meldrum C; deFazio A; Emmanuel C; George J; Dobrovic A; Birrer MJ; Webb PM; Stewart C; Friedlander M; Fox S; Bowtell D; Mitchell G J Clin Oncol; 2012 Jul; 30(21):2654-63. PubMed ID: 22711857 [TBL] [Abstract][Full Text] [Related]
19. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976 [TBL] [Abstract][Full Text] [Related]
20. The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: a retrospective cohort study. So KA; Hong JH; Jin HM; Kim JW; Song JY; Lee JK; Lee NW Gynecol Oncol; 2014 Mar; 132(3):551-5. PubMed ID: 24440470 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]